Studien & Referenzen

Transferfaktoren Dermatologie

1) Wong VG, Kirkpatrick CH. Immunologic reconstitution in a patient with keratoconjunctivitis, superficial candidiasis and hy-poparathyroidism: the role of immunocompetent lymphocyte transfusion and transfer factor. Trans Am Ophthalmol Soc. 1973;71:254-67.
2) Schwarz MA, Gutterman JU, Burgess MA, Heilbrun LK, Murphy WK, Bodey GP, et al. Chemoimmunotherapy of disseminatedmalignant melanoma with DTIC-BCG, transfer factorpmelphalan. Cancer. 1980;45:2506-15.
3) Ortiz A, Delgado 0, Rojas Z. Transfer factor in the treatment of laryngeal papillomatosis. Apropos of 2 cases treated at the Ca-racas University Hospital. An Otorrinolaringol Ibero Am. 1981;8:289-94.
4) Flores SG, Gomez VI, Orea SM, Lopez T], Serrano E, Rodriguez A, et al. Transfer factor as specific immunomodulator in the tre-atment of moderate-severe atopic dermatitis. Rev Alerg Mex. 2005;52:215-20
5) Orozco TT, Solano MO, Sandoval GF, Vera JG, Parra SE. Inflammatory mediators in patients with atopic dermatitis after treatment with transfer factor. Rev Alerg Mex. 2004;51:151-4.
6) Garc'a Al, Flores SG, Orea SM, Serrano E, Estrada PS. Lymphocyte apoptosis in atopic dermatitis treated with transfer factor.
Rev Alerg Mex. 2003;50:3-7.

7) Sosa M, Flores SG, Estrada PS, Orea SM, Go mez V). Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis. Rev Alerg Mex. 2001;48:56-64...
8) Cordero MA, Flores SG, Orea SM, Estrada PS, Serrano ME. Safety and efficacy of treatment for severe atopic dermatitis with cyclosporin A and transfer factor. Rev Alerg Mex. 1999;46:49-57.
9) Valdes SA, Fernandez OC, Gomez EH, Gillama NE, Lastra AG, Lopez SP. Atopic dermatitis. Treatment with transfer factor. A con-trolled clinical trial. Rev Alerg. 1991;38:158-62.
10) Navarro CD, Serrano ME, Orea M, Estrada PS, Teran OL, Gomez V), et al. Transference factor in moderate and severe atopic dermatitis. Rev Alerg Mex. 1996;43:116-23.
11) Zachariae H, Grunnet E, Ellegaard J, Thestrup-Pedersen K. IgE, T cells and transfer factor in mycosis fungoides. Br Med J. 1978;1:854.
12) Silvino G, Rubertelli M, Cristofolini M, Sagramoso Z, Pisciolli F, Dalri P. Treat- ment with transfer factor of herpes zoster varicella infection in Hodgkin's disease. Haematologica. 1978;63:56-60.
13) Garca-Caldero'n PA, Alomar A, Garc'a-Caldero'n JV, Vich JM, De Moragas IM. Therapy with transfer factor in a case of recidiva-ting herpes with polymorphous erythema. Med Cutan Ibero Lat Am. 1977;5:361-6.

14) Escudero GR, Simon MA, Pino CE, Moreno IR. Treatment of candidasis granu- loma with "transfer factor". Actas Dermosifilio-gr. 1976;67:589-98.
15) DeMoragasVI,NogueraT),Garc a-Calderon. Chronicmucocutaneouscandi- diasis. Transfer factor and iron metabolism. Med Cutan Ibero Lat Am. 1974;2:183-92.
16) Faber WR, Leiker DL, Nengerman IM, Schellekens PT. A placebo controlled clinical trial of transfer factor in lepromatous lepro-sy. V. 1979;35:45-52.
17) Estrada P, Nagaya A, Serrano E, Rodriguez O, Santamari a V, Ondarza R, et al. Comparative study of transfer factor and acy-clovir in the treatment of herpes zoster. Int J Immunopharmacol. 1998;20:521-35.
18) Stevens DA, Ferrington RA, Merigan TC, Marinkovich VA. Randomized trial of transfer factor treatment of human warts. ClinExp Immunol. 1975;21: 520-4.

​

Allergie

Transfer factor is not alergenic and it's well described that the long term oral administration of Transfer factor is save (1,2). There are not known cases of persons that has taken Transfer factor and had allergic reactions.
1) Wilson GB, Poindexter C, Fort JD, Ludden KD. De novo initiation of specific cellmediated immune responsiveness in chickens by transfer factor (specific immunity inducer) obtained from bovine colostrum and milk. Acta Virol. 1988;32:6-18.
2) Hernandez F. Ultrastructural analysis of milk fat globule membranes of colostrum and human milk. Rev Biol Trop. 1983;31:245-50.

​

Hypoparathyroidism (Schilddrüsenunterfunktion)

1) Wong VG, Kirkpatrick CH. Immunologic reconstitution in a patient with keratoconjunctivitis, superficial candidiasis and hypoparathyroidism: the role of immunocompetent lymphocyte transfusion and transfer factor. Trans Am Ophthalmol Soc. 1973;71:254-67.

​

​

Infektionen

1) Fabre RA, Perez TM, Aguilar LD, Rangel M), Estrada-Garcia I, Hernandez-Pando R, et al. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin Exp Immunol. 2004;136:215-23.
2) Konlee M. New treatments for hepatitis B and C [antigen-specific transfer for A, B & C (chisolm biologicals) and thymate]. Posit Health News. 1998; 17:19-21.
3) Stevens DA, Ferrington RA, Merigan TC, Marinkovich VA. Randomized trial of transfer factor treatment of human warts. ClinExp Immunol. 1975;21: 520-4
4) Ortiz A, Delgado O, Rojas Z. Transter factor in the treatment of laryngeal papillomatosis. Apropos of 2 cases treated at the Caracas University Hospital. An Otorrinolaringol Ibero Am. 1981;8:289-94.
5) Silvino G, Rubertelli M, Cristofolini M, Sagramoso Z, Pisciolli F, Dalri P. Treat- ment with transfer factor of herpes zoster varicella infection in Hodgkin's disease. Hematologica. 1978;63:56-60.
6) Estrada P, Nagaya A, Serrano E, Rodriguez O, Santamari a V, Ondarza R, et al. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int | Immunopharmacol. 1998;20:521-35.

​

​

Autoimmunerkrankungen

1) 2) Collins RC, Espinoza LR, Plank CR, Ebers GC, Rosenberg RA, Zabriskie JB. A double-blind trial of transfer factor vs placebo in multiple sclerosis patients. Clin Exp Immunol. 1978;33:1-11.
Zabriskie JB, Espinoza LR, Plank CR, Collins RC. Cell-mediated immunity to viral antigens in multiple sclerosis. Acta Neurol
Scand. 1977;55:239
3) Lamoureux G, Cosgrove J, Duquette P, Lapierre Y, Jolicoeur R, Vanderland F. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin Exp Immunol. 1981;43:557-64.
4) Romano EL, Pulido M, Layrisse Z, Malave I. Treatment of patients with multiple sclerosis with transfer factor. Acta Cient Venez. 1978;29:49-52.
5) Borkowsky W, Karpatkin S. Leukocyte migration inhibition of buffy coats from patients with autoimmune thrombocytopenic purpura when exposed to nor- mal platelets: modulation by transfer factor. Blood. 1984;63:83-7.
6) Transfer Factor: An in vivo study in nine patients with fibromyalgia. Robertson R. April 27th 2000.

​

​

Allgemein

1) Transfer factors in medical therapy. Sánchez-González DI, Sosa-Luna CA, Vásquez-Moc-
tezuma I. Med Clin (Barc). 2011 Sep 10;137(6):273-7. doi: 10.1016/j.medcli.2010.05.002. Epub
2010 Jun 18.

​

Ataxiatelangiectasia

1) Garcia Urra D, Pino Corral E, Ceballos Hernansanz A, Varela de Seijas SE, Campos Castello J. Ataxia-telangiectasia: treatment with transfer factor. Arch Neurobiol. 1981;44:3-10.

​

Allergien und Asthma

1) Kesarwala HH, Prasad RV, Szep R, Oldman E, Lane S, Papageorgiou PS. Transfer factor therapy in hyperimmunoglobulinaemia Esyndrome. Clin Exp Immunol. 1979;36:465-72.
2) Valdes SA, Martin RO, Lastra AG. Treatment of extrinsic bronchial asthma with transfer factor. Rev Alerg Mex. 1993;40:124-31.
3) Salazar VR, Mejia OJ. Use of transfer factor in allergic bronchial asthma. Rev Alerg. 1993;40:42-5.
4) Zachariae H, Grunnet E, Ellegaard I, Thestrup-Pedersen K. IgE, T cells and transfer factor in mycosis fungoides. Br Med J. 1978;1:854.

​

Eisenstoffwechsel

1) De Moragas VJ, NogueraT),Garcia-Calderon. Transfer factor and iron metabolism. Med Cutan Ibero Lat Am. 1974;2:183-92.

​

Krebs

1) Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100:57-70.

2) Español T, Padulles I, Prats J. Neuroblastoma and transfer factor. Dev Biol Stand. 1977;38:331-3.
3) Hainaut J, Challan-Belval P, Haguenauer G, Pellegrin J, Allard P, Kermarec J. Effect of transfer factor on the immunity state of patients with bronchopulmonary cancer. A report on 12 cases. Ann Med Interne. 1979;130:517-21.
4) See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest. 2002;31:137-53.
5) Levin AS, Byers VS, Fudenberg HH, Wybran J, Hackett Al, Johnston JO, et al. Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor. J Clin Invest. 1975;55:487-99.
6) Schwarz MA, Gutterman JU, Burgess MA, Heilbrun LK, Murphy WK, Bodey GP, et al. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factorbmelphalan. Cancer. 1980;45:2506-2515
Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R, Arrieta O. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res. 2005;24:575-83.
8) Benjamini E, Rennick DM. Cancer immunotherapy: facts and fancy. CA Cancer J Clin. 1979;29:362-70.

9) Brandes LI, Goldenberg G). In vitro transfer of cellular immunity against nasopharyngeal carcinoma using transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Res. 1974;34:3095-101.
10) Goldenberg G), Brandes LJ. In vivo and in vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor. Cancer Res. 1976;36:720-3.
11) Corrado F, Pizza G, de Vinci C, Corrado G. Immunotherapy with transfer factor in hormone-resistant metastasized carcinoma of the prostate. Arch Esp Urol. 1989;42:191-6.

​

Mehr über die Wissenschaft

White Studies & Publications

Physicians Desk Reference (PDR) 

Nachhaltige Produktion

​

​

​

​